Biopharmaceuticals Market Research Report - Global Forecast till 2025

Biopharmaceuticals Market Research Report - Global Forecast till 2025

ID: MRFR/HC/6967-HCR | November, 2019 | Region: Global | 90 pages | Half-Cooked Research Reports

Market Forecast


Biopharmaceuticals Market is expected to hold a value of USD 394,998.5 Million by 2025 at a CAGR of 8.99%.


Market Synopsis


Biopharmaceuticals are medical drugs produced using biotechnology. Biopharmaceuticals can be proteins (including antibodies), nucleic acids (DNA, RNA, or antisense oligonucleotides) that are used for therapeutic or in vivo diagnostic purposes. These are produced by various means, including direct extraction from a native (non-engineered) biological source. The first such biopharmaceutical approved for therapeutic use was recombinant human insulin (RHI, trade name Humulin), which was developed by Genentech and marketed by Eli Lilly and Company in 1982. Growing market demand for biopharmaceuticals, rising investment by major companies on research & development of biopharmaceuticals, the high incidence rate of chronic diseases, and increasing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases is expected to drive the market growth. As of September 2019, approximately six in 10 adults in the US suffer from a chronic disease. Moreover, rising geriatric population and increasing technological advancements are also anticipated to fuel the market growth.


Market Influencer


The involvement of major pharmaceutical companies such as Abbvie Inc., Eli Lilly and Company, and Novartis AG are positively influencing the market growth.


Market Drivers




  • Increasing investment by major companies in biopharmaceuticals research & development (R&D)




  • Increasing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases




  • The high incidence rate of chronic diseases is increasing the demand for biopharmaceuticals, hence driving the market growth. As of 2018, nearly 45% of Americans suffer from a chronic disease.




  • Rising geriatric population. As of 2019, one in 6 people in the world is aged more than 65 years.




  • Increasing technological advancements




Market Restraints



  • Stringent government regulations

  • Availability of low-cost biosimilars

  • Risk of side-effects associated with biopharmaceuticals


Segmentation


By Product Type




  • Monoclonal Antibodies: The largest segment of the market. Researches carried out with the help of monoclonal antibodies is increasing. Monoclonal antibodies are manufactured using identical immune cells that are clones of a unique parent cell.




  • Recombinant Growth Factors: They are a group of proteins that stimulate the growth of the cell. These are further segmented into erythropoietin and granulocyte colony-stimulating factor (G-CSF). Erythropoietin is a type of hormone that is produced by the kidneys. G-CSF is a type of glycoprotein that can stimulate the bone marrow to produce granulocytes and stem cells and ultimately release them in the bloodstream.




  • Purified Proteins: These can be further segmented into four subsegments—leukemia inhibitory factor, P53 protein, P38 protein, and other purified proteins. Leukemia inhibitory factor or LIF is a type of interleukin 6 class cytokine that can affect the cell growth by inhibiting differentiation. P53 is a tumor protein, which is an isoform of a protein encoded by homologous genes in various organisms. P38 protein is a class of mitogen-activated protein kinases that are responsive to cytokines, ultraviolet irradiation, heat shock, osmotic shock, and other stress stimuli.




  • Recombinant Proteins: They are made from cloned DNA sequences that usually encode a protein or an enzyme with known function. These can be further divided into serum albumin, amyloid protein, defensin, transferrin, and others. Serum albumin is found in the blood and is the most abundant protein found in the human blood plasma. Amyloid proteins are aggregates of proteins that become folded into a particular shape and can allow many copies of that protein to stick together, forming fibrils. Defensins are small cysteine-rich cationic proteins that function as host defense peptides. Transferrin are iron-binding blood plasma glycoproteins that have the ability to control the level of free iron in biological fluids.




  • Recombinant Hormones: They are produced from fragments of growth hormone and human placental lactogen.




  • Vaccines: They are a type of biological preparation that can protein active acquired immunity against a particular disease. Vaccines have been further segregated into recombinant vaccines, conventional vaccines, and others. Recombinant vaccines are produced using recombinant DNA technology. They have been further divided into cancer vaccines, malaria vaccines, Ebola vaccines, hepatitis B vaccines, tetanus vaccines, diphtheria vaccines, cholera vaccines, and others. Conventional vaccines act as an immunological base to fight against the most porcine diseases. These are further segmented into polio vaccines, pox vaccines, and others. Vaccines are the fastest-growing segment owing to rising awareness regarding chronic diseases.




  • Synthetic Immunomodulators: They are a type of medication that is used to help regulate or normalize the immune system. These are further segmented into cytokines, interferons, interleukins; tumor necrosis factor (TNF); and others.




  • Others: This segment includes recombinant enzymes allogenic & autologous products and acellular products.




By Application




  • Oncology: The largest segment owing to the rising prevalence of cancer. There were 1,735,350 new cases of cancer in the US in 2018.




  • Inflammatory and Infectious Diseases: Infectious diseases include cholera, diphtheria, and typhoid. Inflammatory conditions include tuberculosis, rheumatoid arthritis, and sinusitis.




  • Autoimmune Disorders: These include diseases such as inflammatory bowel disease, multiple sclerosis, and diabetes.




  • Metabolic Disorders: These types of disorders occur when abnormal chemical reactions in the body hamper the normal metabolic process.




  • Hormonal Disorders: These include various endocrine disorders such as adrenal insufficiency disorder and hyperthyroidism.




  • Disease Prevention: Vaccines are the biopharmaceuticals used for the prevention of chronic diseases.




  • Cardiovascular Diseases: These include coronary heart disease, arrhythmia, and peripheral artery disease.




  • Neurological Diseases: These include diseases such as Parkinson’s disease and epilepsy. The rising prevalence of neurological disorders is expected to account for the fastest growth of the segment. In the US, 1.8% of the population have been suffering from active epilepsy as of 2016.




  • Others: Other applications of biopharmaceuticals include blood disorders and other rare disorders.




By Region



  • Americas: The largest regional market. The prevalence of chronic diseases, such as cancer, is high in the Americas. Approximately 9.6 million people died suffering from cancer as of September 2018. Moreover, the presence of significant biopharmaceutical companies such as Pfizer, Inc., Amgen Inc., Eli Lilly and Company, and Bristol Myers Squibb Company is expected to drive the market growth.



  • Europe: Increasing geriatric population, well-developed healthcare infrastructure, and high prevalence of neurological diseases are expected to drive the market growth.



  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people suffering from diseases such as diabetes and cancer. Furthermore, the region has a supportive regulatory framework for the approval of biopharmaceuticals, which drives market growth.



  • Middle East & Africa: The market is expected to show significant growth due to the rising patient population suffering from various chronic diseases. Middle Eastern market is expected to show more growth as compared to the African market, owing to the presence of developed countries such as Saudi Arabia and Oman.


Key Players



  • Pfizer, Inc. (US)

  • Amgen Inc. (US)

  • Eli Lilly and Company (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Johnson & Johnson (US)

  • Gilead Sciences, Inc. (US)

  • AstraZeneca (UK)

  • Abbvie Inc. (US)

  • Sanofi (France)

  • Bristol-Myers Squibb Company (US)

  • Sandoz International GmbH (Germany)

  • Novo Nordisk A/S (Denmark)

  • GlaxoSmithKline PLC (UK)

  • Merck KGaA (Germany)

  • Biocon (India)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis


6. GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE

6.1. Overview

6.2. Monoclonal Antibodies

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.3. Recombinant Growth Factors

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.3.1. Erythropoietin

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.3.2. Granulocyte Colony Stimulating Factor

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4. Purified Proteins

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4.1. Leukemia Inhibitory Factor (LIF)

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4.2. P53 Protein

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4.3. P38 Protein

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4.4. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5. Recombinant Proteins

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5.1. Serum Albumin

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5.2. Amyloid Protein

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5.3. Defensin

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5.4. Transferrin

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5.5. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.6. Recombinant Hormones

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7. Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1. Recombinant Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.1. Cancer Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.2. Malaria Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.3. Ebola Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.4. Hepatitis B Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.5. Tetanus Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.6. Diptheria Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.7. Cholera Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.1.8. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.2. Conventional Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.2.1. Polio Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.2.2. Pox Vaccines

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.2.3. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7.3. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.8. Synthetic Immunomodulators

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.8.1. Cytokines, Interferones, Interleukins

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.8.2. Tumor Necrosis Factor (TNF)

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.8.3. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.9. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7. GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION

7.1. Overview

7.2. Oncology

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.3. Inflammatory and Infectious Diseases

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.4. Autoimmune Disorders

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.5. Metabolic Disorders

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.6. Hormonal Disorders

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.7. Disease Prevention

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.8. Cardiovascular Diseases

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.9. Neurological Diseases

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.10. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8. GLOBAL BIOPHARMACEUTICALS MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Biopharmaceuticals Market

9.5. Competitive Benchmarking

9.6. Leading Players in terms of Number of Developments in the Global Biopharmaceuticals Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2018

9.8.2. Major Players R&D Expenditure 2018

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Pfizer, Inc.

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Amgen Inc.

10.2.1. Company Overview

10.2.2. Product Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Eli Lilly and Company

10.3.1. Company Overview

10.3.2. Product Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. F. Hoffmann-La Roche Ltd

10.4.1. Company Overview

10.4.2. Product Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Johnson & Johnson

10.5.1. Company Overview

10.5.2. Product Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Gilead Sciences, Inc.

10.6.1. Company Overview

10.6.2. Product Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. AstraZeneca

10.7.1. Company Overview

10.7.2. Product Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Abbvie Inc.

10.8.1. Company Overview

10.8.2. Product Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Sanofi

10.9.1. Company Overview

10.9.2. Product Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Bristol-Myers Squibb Company

10.10.1. Company Overview

10.10.2. Product Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Sandoz International GmbH

10.11.1. Company Overview

10.11.2. Product Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Novo Nordisk A/S

10.12.1. Company Overview

10.12.2. Product Overview

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

10.13. GlaxoSmithKline PLC

10.13.1. Company Overview

10.13.2. Product Overview

10.13.3. Financial Overview

10.13.4. Key Developments

10.13.5. SWOT Analysis

10.13.6. Key Strategies

10.14. Merck KGaA

10.14.1. Company Overview

10.14.2. Product Overview

10.14.3. Financial Overview

10.14.4. Key Developments

10.14.5. SWOT Analysis

10.14.6. Key Strategies

10.15. Biocon

10.15.1. Company Overview

10.15.2. Product Overview

10.15.3. Financial Overview

10.15.4. Key Developments

10.15.5. SWOT Analysis

10.15.6. Key Strategies

10.16. Others

11. APPENDIX

11.1. References

11.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL BIOPHARMACEUTICALS MARKET SYNOPSIS, 2019–2025

TABLE 2 GLOBAL BIOPHARMACEUTICALS MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)

TABLE 3 GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 4 GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 5 GLOBAL BIOPHARMACEUTICALS MARKET, BY REGION, 2019–2025 (USD MILLION)

TABLE 6 NORTH AMERICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 7 NORTH AMERICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 8 US: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 9 US: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 10 CANADA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 11 CANADA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 12 LATIN AMERICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 13 LATIN AMERICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 14 EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 15 EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 16 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 17 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 18 EASTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 19 EASTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 20 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 21 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2025 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2025 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOPHARMACEUTICALS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOPHARMACEUTICALS MARKET

FIGURE 4 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY PRODUCT TYPE, 2018 (%)

FIGURE 5 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION, 2018 (%)

FIGURE 6 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY REGION, 2018 (%)

FIGURE 7 AMERICAS: BIOPHARMACEUTICALS MARKET SHARE BY REGION, 2018 (%)

FIGURE 7 NORTH AMERICA: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 8 EUROPE: BIOPHARMACEUTICALS MARKET SHARE, BY REGION, 2018 (%)

FIGURE 9 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 10 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 11 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 12 GLOBAL BIOPHARMACEUTICALS MARKET: COMPANY SHARE ANALYSIS, 2018 (%)

FIGURE 13 PFIZER, INC..: KEY FINANCIALS

FIGURE 14 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 15 PFIZER, INC.: REGIONAL REVENUE

FIGURE 16 AMGEN INC.: KEY FINANCIALS

FIGURE 17 AMGEN INC.: SEGMENTAL REVENUE

FIGURE 18 AMGEN INC.: REGIONAL REVENUE

FIGURE 19 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 20 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 21 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 22 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 24 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 25 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 26 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 27 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 28 GILEAD SCIENCES, INC.: KEY FINANCIALS

FIGURE 29 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE

FIGURE 30 GILEAD SCIENCES, INC.: REGIONAL REVENUE

FIGURE 31 ASTRAZENECA: KEY FINANCIALS

FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 33 ASTRAZENECA: REGIONAL REVENUE

FIGURE 34 ABBVIE INC.: KEY FINANCIALS

FIGURE 35 ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 36 ABBVIE INC.: REGIONAL REVENUE

FIGURE 37 SANOFI: KEY FINANCIALS

FIGURE 38 SANOFI: SEGMENTAL REVENUE

FIGURE 39 SANOFI: REGIONAL REVENUE

FIGURE 40 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 41 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 43 SANDOZ INTERNATIONAL GMBH: KEY FINANCIALS

FIGURE 44 SANDOZ INTERNATIONAL GMBH: SEGMENTAL REVENUE

FIGURE 45 SANDOZ INTERNATIONAL GMBH: REGIONAL REVENUE

FIGURE 46 NOVO NORDISK A/S: KEY FINANCIALS

FIGURE 47 NOVO NORDISK A/S: SEGMENTAL REVENUE

FIGURE 48 NOVO NORDISK A/S: REGIONAL REVENUE

FIGURE 49 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 50 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 51 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 52 MERCK KGAA: KEY FINANCIALS

FIGURE 53 MERCK KGAA: SEGMENTAL REVENUE

FIGURE 54 MERCK KGAA: REGIONAL REVENUE

FIGURE 55 BIOCON: KEY FINANCIALS

FIGURE 56 BIOCON: SEGMENTAL REVENUE

FIGURE 57 BIOCON: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Biopharmaceuticals Market